Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies

Glioblastoma, the most common primary brain tumor in adults, has an inauspicious prognosis, given that overcoming the blood-brain barrier is the major obstacle to the pharmacological treatment of brain tumors. As neoangiogenesis plays a key role in glioblastoma growth, the US Food and Drug Administr...

Full description

Saved in:
Bibliographic Details
Published in:Nanotechnology 2015-06, Vol.26 (25), p.255102-255102
Main Authors: Battaglia, Luigi, Gallarate, Marina, Peira, Elena, Chirio, Daniela, Solazzi, Ilaria, Giordano, Susanna Marzia Adele, Gigliotti, Casimiro Luca, Riganti, Chiara, Dianzani, Chiara
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - therapeutic use
anti-VEGF
BBB
bevacizumab
Bevacizumab - administration & dosage
Bevacizumab - chemistry
Bevacizumab - therapeutic use
Brain
Cells, Cultured
coacervation
Drug Carriers - chemistry
Fatty Acids - chemistry
Glioblastoma - drug therapy
Human Umbilical Vein Endothelial Cells
Humans
HUVEC
Hydrophobic and Hydrophilic Interactions
In Vitro Techniques
In vitro testing
ion pair
Lipids
Nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Obstacles
Particle Size
Patients
Permeability
Permeation
solid lipid nanoparticles
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma, the most common primary brain tumor in adults, has an inauspicious prognosis, given that overcoming the blood-brain barrier is the major obstacle to the pharmacological treatment of brain tumors. As neoangiogenesis plays a key role in glioblastoma growth, the US Food and Drug Administration approved bevacizumab (BVZ), an antivascular endothelial growth factor antibody for the treatment of recurrent glioblastoma in patients whose the initial therapy has failed. In this experimental work, BVZ was entrapped in solid lipid nanoparticles (SLNs) prepared by the fatty-acid coacervation technique, thanks to the formation of a hydrophobic ion pair. BVZ activity, which was evaluated by means of four different in vitro tests on HUVEC cells, increased by 100- to 200-fold when delivered in SLNs. Moreover, SLNs can enhance the permeation of fluorescently labelled BVZ through an hCMEC D3 cell monolayer-an in vitro model of the blood brain barrier. These results are promising, even if further in vivo studies are required to evaluate the effective potential of BVZ-loaded SLNs in glioblastoma treatment.
ISSN:0957-4484
1361-6528
DOI:10.1088/0957-4484/26/25/255102